Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 6 recruiting now early-phase tilt

Psychotic Disorders: early-phase trial registry

6 of 23 indexed Psychotic Disorders trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #724 of 28,707 conditions by registered trial count.

23 US clinical trials · 6 currently recruiting · #724 of 28,707 conditions by registered trial count

Psychotic Disorders: 23 US clinical trials tracked, 6 recruiting.

Psychotic Disorders is the subject of 23 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is VA Office of Research and Development, running 4 of these trials.

Enrollment posture brief

Registry condition psychotic-disorders

OPEN 6 | RECR 26% | LATE 2 | EARLY 6 | RANK #724 | SPON 4

Nearest open-share peer: Parkinson's Disease (26% recruiting · 161 trials)

Breast Cancer Stage II47.8%Advanced Non-Small-Cell Lung39.1%Anxiety Disorder30.4%Barrett's Esophagus26.1%Psychotic Disorders (this)26%
Open-enrollment share among volume-matched conditions near Psychotic Disorders

Psychotic Disorders lists 6 open slots (26% of 23 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Psychotic Disorders on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Psychotic Disorders is recruiting below its size-band peers.

    6 of 23 indexed trials (26.1%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Psychotic Disorders research.

    VA Office of Research and Development accounts for 4 of 23 trials (17.4%). 16 distinct sponsors appear on at least one study for this condition label.

  3. Typical Psychotic Disorders enrolment sits around 133 participants.

    Median target enrolment is 133 among the 23 trials that report a genuine target (sentinel values excluded). 9 of those (39.1%) plan for fewer than 100 participants.

  4. Psychotic Disorders research is mostly interventional.

    21 interventional and 2 observational studies make up this index (91.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 23Phase 42

Open and recent trials

23 total, page 1 of 1

RECRUITING NA 2,500 participants

Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders

Maastricht University Medical Center

NCT05656469

RECRUITING NA 480 participants

Racial Disparities in the Expression of Paranoia

Indiana University

NCT07460453

RECRUITING NA 192 participants

A Preventive Behavioral Intervention for Young Adults With Psychotic Experiences

Massachusetts General Hospital

NCT06929442

RECRUITING NA 190 participants

CBT-CP for Veterans With SMI

VA Office of Research and Development

NCT06758414

RECRUITING NA 70 participants

Development of a Transdiagnostic Intervention for Adolescents at Risk for Serious Mental Illness

Massachusetts General Hospital

NCT05962879

RECRUITING NA 69 participants

A Novel Peer-Delivered Recovery-Focused Suicide Prevention Intervention for Veterans With Serious Mental Illness

VA Office of Research and Development

NCT05537376

ACTIVE NOT RECRUITING NA 220 participants

Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial

University of California, Los Angeles

NCT04338152

ACTIVE NOT RECRUITING NA 174 participants

Reconnecting to Ourselves and Others in Virtual Meetings (ROOM)

Massachusetts General Hospital

NCT06360562

ACTIVE NOT RECRUITING Phase 1 80 participants

Cannabinoids, Learning, and Memory

Yale University

NCT02407808

COMPLETED NA 292 participants

Early Detection and Intervention for the Prevention of Psychosis

MaineHealth

NCT00531518

COMPLETED Phase 1 281 participants

Relative Bioavailability of LY03010 Compared to Listed Drug

Luye Pharma Group

NCT04922593

COMPLETED 187 participants

Longitudinal Multimodal Neuroimaging Studies in Patients With First Episode Psychosis

Mclean Hospital

NCT01688765

COMPLETED Phase 4 180 participants

Antipsychotic Discontinuation in Alzheimer's Disease

New York State Psychiatric Institute

NCT00417482

COMPLETED Phase 2 168 participants

Supported Employment: Motivational Enhancement for Entry and Outcome

VA Office of Research and Development

NCT01041976

COMPLETED Phase 2 133 participants

Family-Focused Therapy for Youth With Early-Onset Bipolar or Psychotic Disorders

University of California, Los Angeles

NCT02097563

COMPLETED Phase 4 127 participants

Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics

Johns Hopkins University

NCT00806234

COMPLETED NA 100 participants

Psychosis: Early Detection, Intervention and Prevention

MaineHealth

NCT01597141

COMPLETED 73 participants

Clinical and Biological Characteristics of Psychotic Depression

Stanford University

NCT00576095

COMPLETED Phase 2 38 participants

Treating Smokers With Mental Illness

University of Minnesota

NCT03822416

COMPLETED NA 30 participants

A Concierge Model of CAE Plus LAI in Individuals With Schizophrenia at Risk for Treatment Non-adherence and Homelessness

University Hospitals Cleveland Medical Center

NCT02085447

COMPLETED Early Phase 1 18 participants

Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis

VA Office of Research and Development

NCT01981356

COMPLETED NA 10 participants

Mobile After-Care Intervention to Support Post-Hospital Transition (MACS)

Butler Hospital

NCT03769493

COMPLETED NA 8 participants

Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms

Northwell Health

NCT00169988

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 3
Phase 4 2

Named interventions

Most-linked intervention names on Psychotic Disorders records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

risperidone Drug
2 trials
Supported employment and education Behavioral
1 trials
Psychoeducational multifamily group treatment Behavioral
1 trials
aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine Drug
1 trials
Enhanced standard treatment Behavioral
1 trials
Family-aided Assertive Community Treatment Behavioral
1 trials
Low Intensity Training Behavioral
1 trials
High Intensity Training Behavioral
1 trials

US sites by state

Facility locations filed on Psychotic Disorders trials. A trial with sites in several states counts in each.

California 8 trials
New York 6 trials
Massachusetts 6 trials
Connecticut 3 trials
Maine 2 trials
Maryland 2 trials
Texas 1 trials
South Carolina 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Psychotic Disorders page

23 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Psychotic Disorders condition card totals 23 registered trials; most-linked intervention risperidone; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.